At a glance
- Originator Pharmacia Corporation
- Class Heart failure therapies
- Mechanism of Action Metalloprotease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Connective tissue disorders; Heart failure; Rheumatoid arthritis